TNFRSF4
Overview
TNFRSF4 (OX40, CD134) is a T-cell co-stimulatory receptor in the TNF receptor superfamily. OX40 agonists are under clinical investigation as immunotherapy agents to enhance anti-tumor T-cell responses in solid tumors including nasopharyngeal carcinoma (NPC).
Alterations observed in the corpus
- TNFRSF4 (OX40) is a T-cell co-stimulatory receptor; agonist BAT6026 tested in phase I trials with no significant NPC-specific activity reported to date. PMID:24952746
- OX40; selectively upregulated on-therapy in nivolumab responders in melanoma; nominated as a candidate target for combination immunotherapy PMID:29033130
Cancer types (linked)
- NPC — OX40 agonist BAT6026 is in phase I investigation as an immunotherapy strategy in R/M NPC; no significant activity reported yet. PMID:24952746
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the current corpus.
Therapeutic relevance
- OX40 agonist BAT6026 in phase I testing in NPC; rationale is to augment T-cell co-stimulation in the immunosuppressive NPC tumor microenvironment. PMID:24952746
Open questions
- Clinical activity of OX40 agonists in NPC remains to be established; optimal combination partners (anti-PD-1, chemotherapy) are not defined.
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:29033130
This page was processed by wiki-cli on 2026-05-15.